1729P Influence of recent administration and type of oncological treatment (T) in survival of oncological patients (p) with COVID-19: Experience of Vall d’Hebron University Hospital

Abstract

Background:The cancer population seems to be more susceptible to COVID-19 infection and have worse outcomes. Front of this pandemic, we had to adapt our patient care to protect our patients without compromising their prognosis related to their cancer. The national PRATICOVID study aims to describe the modification of the medical and surgical patient care for this population, according to the recommendations in this context of pandemic, within our hospitals which are strongly mobilized.Methods: We analyzed data from 9 different institutions, 3 Military Hospitals, 4 Academics Hospital, 2 Private Hospital, from oncologists, surgeons, radiotherapists. The primary endpoint was to assess the prevalence of adapted patient care during pandemic. The secondary endpoints were to describe the point of view of clinicians and patients during and after the pandemic.

Addressing the Impact of the COVID-19 Pandemic on Survival Outcomes in Randomized Phase III Oncology Trials

“…Early evidence also suggests that COVID-19 prevalence is disproportionately higher in cancer patients (particularly in those with lung cancer) compared with the general population (Bakouny et al, 2020(Bakouny et al, , 2022Sessa et al, 2022). Notably, however, cancer treatment itself has been shown not to be a risk factor for COVID-19-related mortality (Serrano et al, 2020;Pinato et al, 2020;Seguí et al, 2020;Tapia et al, 2020;García-Illescas et al, 2020;Joerger et al, 2020).…”